$$$$$$$~BIG OTC DD PICKS AND LOW FLOAT MOVERS$$$$$$$

[7Secret7Service7]

$EHVVF Positioned for growth in Canada's combusting Cannabis industry.

Having medical marijuana legalized and recreational to be instituted nationwide by July 1st 2018, Canada is the place to invest now! Canadian cannabis companies have been flying 'High' on the radar for investors around the world. Share-prices have been surging across the board, as investors pour in and companies battle to gain there market share.

The top players in the game are: Aurora Cannabis (NASDAQOTH:ACBFF), Canopy Growth (NASDAQOTH:TWMJF), GW Pharmaceuticals (NASDAQ:GWPH), Insys Pharmaceuticals (NASDAQ:INSY), and MedReleaf (NASDAQOTH:MEDFF)

As the big wigs battle it out, they are buying up and forming partnerships with the stronger smaller companies with promising technologies and bright futures. Just weeks ago we saw the largest hostile take-over in Canadian cannabis history, as Aurora Cannabis Announced it's Intention to Launch a Takeover Bid for CanniMed Therapeutics Inc.

These take-overs and partnerships are creating dream-like opportunities for small-cap investors abroad.

Lets look at a unique partnership between One of Canada's cannabis Giants, MedReleaf (NASDAQOTH:MEDFF) which has second-highest sales and the fourth-highest market cap among the medical cannabis stocks, and a small-cap sleeper Ehave (OTC-EHVVF).


Ehave and MedReleaf have joined forces to develop a branded MedReleaf app utilizing the Ehave Connect mental health informatics platform to advance the study and therapeutic use of medical cannabis. Ehave Connect enables developers, and ultimately prescribers, of medical cannabis to design and monitor treatment plans, track patient compliance, and verify treatment outcomes in a reliable and objective manner.

Together, Ehave and MedReleaf seek to validate and optimize the use of MedReleaf's medical cannabis products as therapeutic treatments for various mental health conditions. Initially, the companies will use Ehave Connect to manage treatment plans and track patient outcomes as part of a clinical trial to evaluate medical cannabis's potential ability to provide relief to persons suffering from post-traumatic stress disorder ("PTSD"). Ultimately, it is anticipated that the MedReleaf App based on the Ehave Connect platform can be used to monitor every step of the medical cannabis treatment life cycle, from diagnosis and treatment planning to medication adherence and outcomes verification.

https://www.otcmarkets.com/stock/EHVVF/news/Ehave-and-MedReleaf-Enter-Partnership-to-Optimize-the-Therapeutic-Potential-of-Medical-Cannabis-Products?id=151088&b=y

Ehave video:

DD page: http://ehvvf.investorsmarketbuzz.com/